Validation of the European Oncology Quality of Life Toolkit

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jul 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new tool called the European Oncology Quality of Life Toolkit (EUonQoL-Kit), which aims to help assess and improve the quality of life (QoL) for cancer patients at different stages of their journey—whether they are currently undergoing treatment, are survivors, or are receiving palliative care. The trial will involve around 4,500 patients from 45 cancer centers across Europe, who will answer questionnaires to help validate this tool. By understanding how patients feel about their quality of life, healthcare providers can better address their needs and improve their care.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of cancer. They should be either currently receiving treatment, have completed treatment and are now considered survivors, or be in palliative care. Participants will complete questionnaires in their native language, and the study will ensure their responses are reliable. Patients will be informed about the study and will need to give their written consent to take part. If someone has difficulties understanding or completing the questionnaires, they may not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or more.
• • Present or past histologically confirmed diagnosis of solid tumour or haematological malignancy.
• • Being in one of these three conditions: A) Patients in active treatment; B) Survivors; C) in Palliative Care.
• • Native tongue or fluent in the language of the questionnaire
• • Written informed consent to the study.
• Exclusion Criteria:
• • Cognitive impairment preventing the completion of the questionnaire